Skip to main content

Table 1 Characteristics of the included studies

From: Intravenous immunoglobulins improve live birth rate among women with underlying immune conditions and recurrent pregnancy loss: a systematic review and meta-analysis

Study

Country

Non-randomized design

Definition RPL

Inclusion criteria

N

Intervention

Outcomes

IVIG (mg/kg)

Cycles

Continued until (weeks of gestation)

Ahmadi et al. (2019)

Iran

Prospective

 ≥ 3 PL before GA of 20 weeks

Age 18–40 years

NK-cell number > 12%

78

400 (ns)

Every 4 weeks

Initiated after pregnancy confirmation

30–32

Live birth

Jafarzadeh et al. (2019)

Iran

Prospective

 ≥ 3 PL before GA of 20 weeks

Age 18–41 years

Immune system abnormality

94

400 (Sandoglobulin)

Every 4 weeks

Initiation not further defined

32

Live birth

Mahmoud et al. (2004)

Kuwait/USA

Prospective

3 PL between GA of 6 and 22 weeks

Positive for APS

15

500

(ns)

Every 4 weeks

Initiated after pregnancy confirmation

34

Live birth

Moraru et al. (2012)

Spain

Prospective

 ≥ 3 PL before GA of 20 weeks

NK-cell number > 12%

NKT-like cells > 10%

24

400

(Privigen or Flebogamma)

Every 3–4 weeks

Initiated after pregnancy confirmation

13

Live birth

200 (Privigen or Flebogamma)

Every 4 weeks

35

Perricone et al. (2008)

Italy

Prospective

 ≥ 3 PL

Systemic lupus erythematosus

24

500 (Flebogamma)

Every 3 weeks

Initiated after pregnancy confirmation

33

Live birth

Ramos-Medina et al. (2014)

Spain

Retrospective

 ≥ 3 PL before GA of 20 weeks

NK-cell number > 12%

NK-cell like number > 10%

121

400 (Privigen or Flebogamma)

Every 3 weeks

Initiated after pregnancy confirmation

1st trimester

Live birth

200 (Privigen or Flebogamma)

Every 4 weeks

35–36

 

Stricker et al. (2005)

USA

Prospective

 ≥ 3 PL

Age > 28 years

Abnormal immunologic tests including among others T-cell counts and NK-cell levels

64

200 (Venoglobulin-S)

Every 4 weeks

Initiated 2 weeks prior to planned conception

26–30

Live birth

Winger et al. (2008)

USA

Retrospective

 ≥ 3 PL

Women with NK-cells > 15% or CD56 number > 12% were offered IVIG

58

400 (ns)

At least once during cycle of conception and/or at least once after pregnancy confirmation

–

Live birth

  1. GA gestational age, IVIG intravenous immunoglobulin, NK natural killer, PL pregnancy loss, RPL recurrent pregnancy loss, ns not specified